Randomized phase II trial of weekly dose-intensive chemotherapy or amrubicin plus cisplatin chemotherapy following induction chemoradiotherapy for limited-disease small cell lung cancer (JCOG1011).
暂无分享,去创建一个
Y. Ohe | K. Goto | H. Murakami | T. Seto | T. Tamura | Hiroshi Tanaka | N. Nogami | F. Oshita | N. Yamamoto | S. Ishikura | H. Okamoto | I. Sekine | H. Harada | M. Wakabayashi
[1] M. Satouchi,et al. Feasibility study of chemoradiotherapy followed by amrubicin and cisplatin for limited‐disease small cell lung cancer , 2016, Cancer science.
[2] Daniel J Sargent,et al. Randomized Phase II Clinical Trials , 2014, Journal of biopharmaceutical statistics.
[3] N. Saijo,et al. Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] H. Tsukuma,et al. Trends in Lung Cancer Incidence by Histological Type in Osaka, Japan , 2008, Japanese journal of clinical oncology.
[5] J. Crowley,et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the Tumor, Node, Metastasis Classification for Lung Cancer , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[6] D. Ettinger,et al. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] H. Ohmatsu,et al. Dose intensive chemotherapy for limited-stage (LS) small cell lung cancer (SCLC): A phase II study , 2005 .
[8] N. Saijo,et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Sin-Ho Jung,et al. Etoposide, ifosfamide and cisplatin (VIP) plus concurrent radiation therapy for previously untreated limited small cell lung cancer (SCLC): a Hoosier Oncology Group (HOG) phase II study. , 2002, Lung cancer.
[10] R. Komaki,et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. , 1999, The New England journal of medicine.
[11] N. Saijo,et al. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] N. Saijo,et al. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study. , 2014, The Lancet. Oncology.
[13] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[14] G. Scuderi**,et al. Survival analysis. , 1994, The Journal of bone and joint surgery. British volume.
[15] Rupert G. Miller,et al. Survival Analysis , 2022, The SAGE Encyclopedia of Research Design.